Marker Therapeutics (NASDAQ:MRKR) Stock Price Down 0.8%

Marker Therapeutics, Inc. (NASDAQ:MRKR)’s stock price fell 0.8% during mid-day trading on Tuesday . The stock traded as low as $4.61 and last traded at $4.67. 11,244 shares were traded during trading, a decline of 45% from the average session volume of 20,446 shares. The stock had previously closed at $4.71.

Analyst Upgrades and Downgrades

Separately, LADENBURG THALM/SH SH assumed coverage on shares of Marker Therapeutics in a research note on Tuesday, April 30th. They issued a “buy” rating and a $11.00 target price on the stock.

Marker Therapeutics Trading Down 0.8 %

The company’s 50-day moving average price is $4.13 and its 200-day moving average price is $4.32.

Marker Therapeutics (NASDAQ:MRKR) last released its earnings results on Wednesday, May 15th. The company reported ($0.27) earnings per share for the quarter. The business had revenue of $1.24 million during the quarter. Marker Therapeutics had a negative net margin of 142.62% and a negative return on equity of 39.89%. On average, research analysts expect that Marker Therapeutics, Inc. will post -1.64 EPS for the current fiscal year.

Institutional Trading of Marker Therapeutics

An institutional investor recently raised its position in Marker Therapeutics stock. International Assets Investment Management LLC raised its position in Marker Therapeutics, Inc. (NASDAQ:MRKR) by 1,000.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,000 shares of the company’s stock after acquiring an additional 10,000 shares during the quarter. International Assets Investment Management LLC owned approximately 0.12% of Marker Therapeutics worth $60,000 at the end of the most recent reporting period. 22.39% of the stock is owned by institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.